Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 421
Filtrar
Más filtros

Intervalo de año de publicación
1.
Zhen Ci Yan Jiu ; 48(12): 1209-1217, 2023 Dec 25.
Artículo en Inglés, Chino | MEDLINE | ID: mdl-38146243

RESUMEN

OBJECTIVES: To investigate the effects of electroacupuncture(EA) combined with bone marrow mesen-chymal stem cells(BMSCs) transplantation on the endometrium of rats with intrauterine adhesions(IUA), so as to explore the possible mechanisms underlying their combined therapeutic effects. METHODS: Forty adult female SD rats were randomly divided into control, model, cell, and combined groups. The IUA rat model was established using a dual injury method of mechanical scratching and lipopolysaccharide infection. After successful modeling, on days 1, 3, and 7, rats in the model group received tail vein injection of phosphate buffered solution, while rats in the cell group received tail vein injection of BMSCs suspension for BMSCs transplantation;and rats in the combined group received BMSCs transplantation combined with EA treatment (2 Hz/15 Hz, 1-2 mA), targeting the "Guanyuan"(CV4), bilateral "Zusanli"(ST36) and "Sanyinjiao"(SP6) for 20 min daily for 3 consecutive estrous cycles. After intervention, uterine tissue was collected from 5 rats in each group. Histological analysis was performed using hematoxylin and eosin staining to evaluate endometrial thickness and glandular number. Masson staining was used to assess endometrial fibrosis area. Immunohistochemistry was performed to detect the positive expressions of vascular endothelial growth factor(VEGF), proliferating cell nuclear antigen(PCNA), and estrogen receptor(ER). Western blot analysis was conducted to determine the protein expressions of homeobox A10(HoxA10) and leukemia inhibitory factor(LIF), both key regulators of endometrial receptivity. The remaining 5 rats in each group were co-housed with male rats, and the uterine function recovery was evaluated by assessing the number of embryo implantations. RESULTS: Compared with the control group, the model group showed thinning endometrium(P<0.001), decreased glandular number(P<0.001), increased endometrial fibrosis area(P<0.001), reduced positive expressions of VEGF, PCNA, ER, expressions of HoxA10 and LIF, and decreased embryo implantation number (P<0.001) on the injured side of the uterus. Compared with the model group, the combined group showed a reversal of the aforementioned indicators(P<0.001, P<0.01);the cell group exhibited thicker endometrium(P<0.001) and reduced endometrial fibrosis area(P<0.001). Compared with the cell group, the combined group showed increased endometrial thickness(P<0.01), elevated glandular number(P<0.05), significantly decreased endometrial fibrosis area(P<0.05), enhanced positive expressions of VEGF, PCNA and ER, expressions of HoxA10 and LIF in the endometrium, and a significant increase in embryo implantation number (P<0.001, P<0.05, P<0.01) on the injured side of the uterus, indicating better results than the cell group. CONCLUSIONS: The combination of EA and BMSCs synergistically promotes the repair of damaged endometrium, improves endometrial morphology, reduces fibrosis levels, enhances vascular regeneration and matrix cell proliferation, improves endometrial receptivity, which ultimately facilitates embryo implantation.


Asunto(s)
Electroacupuntura , Trasplante de Células Madre Mesenquimatosas , Enfermedades Uterinas , Humanos , Ratas , Masculino , Femenino , Animales , Factor A de Crecimiento Endotelial Vascular/genética , Antígeno Nuclear de Célula en Proliferación/metabolismo , Antígeno Nuclear de Célula en Proliferación/farmacología , Ratas Sprague-Dawley , Trasplante de Células Madre Mesenquimatosas/métodos , Médula Ósea/patología , Enfermedades Uterinas/genética , Enfermedades Uterinas/terapia , Enfermedades Uterinas/metabolismo , Endometrio/metabolismo , Fibrosis
2.
Bone ; 164: 116514, 2022 11.
Artículo en Inglés | MEDLINE | ID: mdl-35952974

RESUMEN

AIM: Identify new potential biomarkers of osteoporosis at an early stage, by magnetic resonance spectroscopy (MRS), studying early changes in the metabolic profile of bone-marrow fatty acids in women's calcanei during healthy aging and osteoporosis status. METHODS: Single voxel MRS was performed by using a point resolved spectroscopy (PRESS) sequence at 3T. Thirty-four Caucasian women (age range: 22-59 years) were recruited to investigate calcaneus bone marrow. The cohort was constituted of four groups according to age, menopausal status, and T-score evaluated after a DXA examination on the femoral neck. Women were classified in young control (n = 11, mean age = 26.5 ± 3.8 y, age range: 22-34 years), perimenopausal groups (n = 11, mean age = 42.0 ± 3.6 y, age range: 37-47 years), postmenopausal group (n = 9, mean age = 55.4 ± 2.9 y, age range: 50-59 years, mean T-score = -1.70 ± 0.50) and osteoporotic group (n = 6, mean age = 53.0 ± 2.8 y, age range: 50-58 years, mean T-score = -2.54 ± 0.10). The total lipid content (TL), the Unsaturation Index (UI), and the fraction of unsaturated/polyunsaturated fatty acid (fUFA and fPUFA) were calculated. RESULTS: TL was significantly correlated with age (r = 0.73, p < 0.001). TL increases linearly with age in the young + perimenopausal population (r = 0.92, p < 0.001) but this trend is not significant in the postmenopausal subject (r = 0.48, p = 0.07). No significant correlation was found between T-Score and TL in postmenopausal and osteoporotic women, whereas a significant correlation was found between TL and time interval (tp) between the age at menopause and the age of the subject at the MRS examination. Conversely, no correlation was found between T-score and tp. The unsaturation index (UI) does not significantly discriminate between osteoporotic, peri- and postmenopausal women. On the other hand, fUFA is significantly different in peri-menopausal and osteoporotic subjects (p = 0.02), while fPUFA is significantly different both between peri- and postmenopausal women (p = 0.05) and postmenopausal and osteoporotic subjects (p = 0.03). Both fUFA and fPUFA did not correlate with subjects' age. CONCLUSION: In the female calcaneus, fUFA and fPUFA are promising measurable quantities for the characterization of bone marrow's composition potentially correlated with the development of osteoporosis, whereas UI does not differentiate between subjects of varying osteoporotic status. The fact that the TL in the calcaneus is correlated with tp, indicates that active metabolic changes are still occurring in these subjects, giving complementary information to the DXA about the changes in bone marrow's composition which may affect the whole bone health.


Asunto(s)
Calcáneo , Osteoporosis Posmenopáusica , Osteoporosis , Absorciometría de Fotón , Adulto , Biomarcadores , Densidad Ósea , Médula Ósea/diagnóstico por imagen , Médula Ósea/patología , Calcáneo/patología , Ácidos Grasos , Femenino , Humanos , Espectroscopía de Resonancia Magnética/métodos , Persona de Mediana Edad , Osteoporosis/diagnóstico por imagen , Osteoporosis/patología , Osteoporosis Posmenopáusica/patología , Adulto Joven
3.
Gan To Kagaku Ryoho ; 49(7): 789-792, 2022 Jul.
Artículo en Japonés | MEDLINE | ID: mdl-35851352

RESUMEN

Suppression of bone marrow function is one of the most common adverse effects of chemotherapy for gastrointestinal cancer. In 3 patients with gastrointestinal cancer who underwent chemotherapy, Ninjin' yoeito(NYT)was found to be effective in preventing this adverse reaction. Patient 1, a 76-year-old woman with rectal carcinoma(pT3N1bM0, pStage Ⅲb), underwent anterior rectal resection. Although chemotherapy(mFOLFOX6)was performed 6 weeks after the operation, the leukocyte and erythrocyte counts were decreased. NYT administration from day 9 of mFOLFOX6 chemotherapy resulted in the maintenance of bone marrow function and allowed continuation of chemotherapy. Patient 2 was a 65-year-old woman who underwent right hemi-colectomy for ascending colon cancer(pT3N0M0, pStage Ⅱ). A partial hepatectomy was performed for the second S8 liver metastasis, and NYT was administered at the time of introduction of mFOLFOX6. In patient 3, an 83-year-old woman who underwent total gastrectomy for gastric cancer(pT4a[SE]N3aM0, pStage Ⅲb), NYT was administered at the same time as the transition to second-line treatment with paclitaxel plus ramucirumab. In all cases, chemotherapy was continued without drug suspension or dose reduction after NYT administration. Thus, NYT may be effective in aiding the continuation of chemotherapy.


Asunto(s)
Panax , Neoplasias Gástricas , Anciano , Anciano de 80 o más Años , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Médula Ósea/patología , Femenino , Hepatectomía , Humanos , Neoplasias Gástricas/cirugía
4.
Blood Adv ; 6(10): 3126-3141, 2022 05 24.
Artículo en Inglés | MEDLINE | ID: mdl-35157757

RESUMEN

Acute myeloid leukemia (AML) is a blood cancer of the myeloid lineage. Its prognosis remains poor, highlighting the need for new therapeutic and precision medicine approaches. AML symptoms often include cytopenias linked to loss of healthy hematopoietic stem and progenitor cells (HSPCs). The mechanisms behind HSPC decline are complex and still poorly understood. Here, intravital microscopy (IVM) of a well-established experimental model of AML allows direct observation of the interactions between healthy and malignant cells in the bone marrow (BM), suggesting that physical dislodgment of healthy cells by AML through damaged vasculature may play an important role. Multiple matrix metalloproteinases (MMPs), known to remodel extracellular matrix, are expressed by AML cells and the BM microenvironment. We reason MMPs could be involved in cell displacement and vascular leakiness; therefore, we evaluate the therapeutic potential of MMP pharmacological inhibition using the broad-spectrum inhibitor prinomastat. IVM analyses of prinomastat-treated mice reveal reduced vascular permeability and healthy cell clusters in circulation and lower AML infiltration, proliferation, and cell migration. Furthermore, treated mice have increased retention of healthy HSPCs in the BM and increased survival following chemotherapy. Analysis of a human AML transcriptomic database reveals widespread MMP deregulation, and human AML cells show susceptibility to MMP inhibition. Overall, our results suggest that MMP inhibition could be a promising complementary therapy to reduce AML growth and limit HSPC loss and BM vascular damage caused by MLL-AF9 and possibly other AML subtypes.


Asunto(s)
Leucemia Mieloide Aguda , Animales , Médula Ósea/patología , Células Madre Hematopoyéticas/patología , Leucemia Mieloide Aguda/tratamiento farmacológico , Leucemia Mieloide Aguda/patología , Metaloproteasas , Ratones , Pronóstico , Microambiente Tumoral
5.
Acta Clin Belg ; 77(5): 868-873, 2022 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-34779361

RESUMEN

OBJECTIVES: For the detection of bone marrow (BM) metastases in patients with neuroblastoma, microscopic BM examination and [123I]MIBG scintigraphy are advised. The aims of this study were to assess the concordance of [123I]MIBG and microscopic BM examination (aspirate and biopsy) in detecting BM involvement and to compare invasive disease in BM biopsies and aspirates, both at diagnosis and before autologous stem cell collection (ASCC). METHODS: Fifty-five patients with stage 4 or stage 4S disease were included, and 37 of them received an autologous hematopoietic stem cell transplantation (AHSCT). The concordance rate was measured and paired binary data were analysed by the McNemar test to look for a systematic difference between diagnostic tests. RESULTS: At diagnosis and before ASCC, we found acceptable concordance rates for [123I]MIBG versus microscopic BM examination (77.1% and 85.3% respectively). Discordant results were found in both directions and at both time points. The concordance rate for biopsy versus aspirate at diagnosis was 80.6%, however, before ASCC a much higher concordance rate between both microscopic examinations was found (94.1%). While none of the aspirates showed neuroblastoma cells before ASCC, two biopsies still showed tumor invasion. CONCLUSION: For patients with neuroblastoma, a [123I]MIBG scintigraphy and a microscopic examination of BM aspirate and its biopsy should be used as complementary tools in the evaluation of BM involvement, and this both at diagnosis and during treatment (before ASCC).


Asunto(s)
Neoplasias Óseas , Neuroblastoma , 3-Yodobencilguanidina , Médula Ósea/diagnóstico por imagen , Médula Ósea/patología , Examen de la Médula Ósea , Neoplasias Óseas/secundario , Humanos , Radioisótopos de Yodo , Neuroblastoma/diagnóstico por imagen , Neuroblastoma/patología , Neuroblastoma/secundario , Cintigrafía
6.
J Bone Miner Res ; 37(3): 420-427, 2022 03.
Artículo en Inglés | MEDLINE | ID: mdl-34954857

RESUMEN

Bone marrow lesions (BML) represent areas of deteriorated bone structure and metabolism characterized by pronounced water-equivalent signaling within the trabecular bone on magnetic resonance imaging (MRI). BML are associated with repair mechanisms subsequent to various clinical conditions associated with inflammatory and non-inflammatory injury to the bone. There is no approved treatment for this condition. Bisphosphonates are known to improve bone stability in osteoporosis and other bone disorders and have been used off-label to treat BML. A randomized, triple-blind, placebo-controlled phase III trial was conducted to assess efficacy and safety of single-dose zoledronic acid (ZOL) 5 mg iv with vitamin D 1000 IU/d as opposed to placebo with vitamin D 1000 IU/d in 48 patients (randomized 2:1) with BML. Primary efficacy endpoint was reduction of edema volume 6 weeks after treatment as assessed by MRI. After treatment, mean BML volume decreased by 64.53% (±41.92%) in patients receiving zoledronic acid and increased by 14.43% (±150.46%) in the placebo group (p = 0.007). A decrease in BML volume was observed in 76.5% of patients receiving ZOL and in 50% of the patients receiving placebo. Pain level (visual analogue scale [VAS]) and all categories of the pain disability index (PDI) improved with ZOL versus placebo after 6 weeks but reconciled after 6 additional weeks of follow-up. Six serious adverse events occurred in 5 patients, none of which were classified as related to the study drug. No cases of osteonecrosis or fractures occurred. Therefore, single-dose zoledronic acid 5 mg iv together with vitamin D may enhance resolution of bone marrow lesions over 6 weeks along with reduction of pain compared with vitamin D supplementation only. © 2021 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).


Asunto(s)
Conservadores de la Densidad Ósea , Enfermedades de los Cartílagos , Densidad Ósea , Conservadores de la Densidad Ósea/efectos adversos , Médula Ósea/patología , Enfermedades de los Cartílagos/patología , Difosfonatos/efectos adversos , Método Doble Ciego , Humanos , Dolor/tratamiento farmacológico , Vitamina D/uso terapéutico , Ácido Zoledrónico/uso terapéutico
7.
S D Med ; 75(11): 488-490, 2022 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-36893024

RESUMEN

Sarcoidosis is primarily a disease of the lungs, and extrapulmonary manifestations are rare. Herein we report a case of isolated bone marrow sarcoidosis presenting as symptomatic hypercalcemia. A 75-year-old female presented with complaints of confusion, dizziness, headaches, and tremulousness. Workup was unremarkable save for hypercalcemia and elevated serum 1,25(OH)D3. Bone marrow biopsy revealed non-caseating granulomas suggestive of sarcoidosis. She was treated with a slow prednisone taper and her symptoms resolved. This case demonstrates the diagnostic and therapeutic challenges associated with a novel presentation and endorses the use of bone marrow biopsy in the workup of sarcoidosis. The risks and benefits of calcium and vitamin D supplementation for steroid-induced bone disease prevention in this population are also discussed.


Asunto(s)
Hipercalcemia , Sarcoidosis , Humanos , Femenino , Anciano , Hipercalcemia/etiología , Hipercalcemia/diagnóstico , Médula Ósea/patología , Sarcoidosis/complicaciones , Sarcoidosis/diagnóstico , Prednisona/uso terapéutico , Calcio
8.
Clin Radiol ; 76(7): 550.e19-550.e28, 2021 07.
Artículo en Inglés | MEDLINE | ID: mdl-33762136

RESUMEN

AIM: To investigate the prognostic significance of bone marrow (BM) 2-[18F]-fluoro-2-deoxy-d-glucose (FDG) uptake in relation to posterior iliac crest BM biopsy (BMB) results in diffuse large B-cell lymphoma (DLBCL). MATERIALS AND METHODS: Pretreatment integrated positron-emission tomography(PET)/computed tomography (CT) images of 512 DLBCL patients who underwent BMB and received rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy were analysed retrospectively. BM uptake was assessed visually and by maximum standard uptake value (SUVmax). Associations with lymphoma-specific survival (LSS) were assessed using Kaplan-Meier and Cox regression analyses. RESULTS: FDG(+) BM was observed in 64 cases (41 focal, 12 heterogeneous, 11 diffuse). This finding distinguished iliac crest involvement (positive in 59 and negative in 453) with 89.6% accuracy (459/512) and 93.6% specificity (424/453). In BMB(+) patients, BM-to-liver SUVmax ratio >1.8 concurred perfectly with FDG(+) BM. During 52 months of follow-up, there were 156 lymphoma-related deaths. In the entire population, multivariate analysis revealed high International Prognostic Index (IPI; p<0.001), old age (p=0.003), bulky disease (p=0.011), BMB(+) (p=0.028), and FDG(+) BM (p=0.019) as independent predictors of worse LSS. In the BMB(+) subgroup, high National Comprehensive Cancer Network-revised IPI (NCCN-IPI; p=0.029) and FDG(+) BM (p=0.008) were significant independent predictors. Among BMB(+) patients with low to low-intermediate NCCN-IPI, FDG(+) BM was associated with significantly worse 2-year LSS (33.3% versus 100%; p=0.017). The same was true among those with high-intermediate NCCN-IPI (34.7% versus 76.9%.; p=0.026). CONCLUSION: Increased BM FDG in DLBCL is a predictor of worse LSS independent of BMB results and other prognostic variables including IPI/NCCN-IPI.


Asunto(s)
Médula Ósea/patología , Linfoma de Células B Grandes Difuso/diagnóstico por imagen , Linfoma de Células B Grandes Difuso/patología , Tomografía Computarizada por Tomografía de Emisión de Positrones , Anciano , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Biopsia , Ciclofosfamida/uso terapéutico , Doxorrubicina/uso terapéutico , Femenino , Fluorodesoxiglucosa F18 , Humanos , Ilion/patología , Linfoma de Células B Grandes Difuso/tratamiento farmacológico , Linfoma de Células B Grandes Difuso/mortalidad , Masculino , Persona de Mediana Edad , Prednisona/uso terapéutico , Pronóstico , Radiofármacos , Estudios Retrospectivos , Rituximab/uso terapéutico , Tasa de Supervivencia , Vincristina/uso terapéutico
9.
Int Immunopharmacol ; 93: 107412, 2021 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-33524801

RESUMEN

Epigallocatechin-3-gallate (EGCG), the primary polyphenol component of green tea, has been shown to inhibit both oxidation and inflammation. However, the exact mechanism through which EGCG exhibits anti-inflammatory effects remains unclear. In this study, we assessed the potential pathways by which EGCG regulates NLRP3 inflammasome activity in vitro. We found that EGCG inhibits caspase-1 activation and IL-1ß secretion by suppressing NLRP3 inflammasome activation in mouse bone marrow-derived macrophages (BMDMs). EGCG was also observed to block NLRP3-mediated ASC speckle formation and to alleviate pyroptosis in BMDMs. In addition, EGCG treatment could improve high-fat diet (HFD)-induced glucose tolerance and prevent NLRP3 inflammasome-dependent inflammation in a mouse model of HFD-induced type 2 diabetes (T2D). Taken together, our results show that EGCG is a general inhibitor of NLRP3 inflammasome activation and administration of EGCG in T2D mice could improve glucose tolerance in vivo.


Asunto(s)
Antiinflamatorios/uso terapéutico , Médula Ósea/patología , Catequina/análogos & derivados , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Inflamasomas/metabolismo , Inflamación/tratamiento farmacológico , Macrófagos/inmunología , Animales , Catequina/uso terapéutico , Células Cultivadas , Dieta Alta en Grasa , Modelos Animales de Enfermedad , Prueba de Tolerancia a la Glucosa , Humanos , Ratones , Ratones Endogámicos C57BL , Proteína con Dominio Pirina 3 de la Familia NLR/metabolismo , Piroptosis
10.
Mol Cell Endocrinol ; 519: 111039, 2021 01 01.
Artículo en Inglés | MEDLINE | ID: mdl-32980418

RESUMEN

Previous studies have demonstrated that the transplantation of alginate-poly-ʟ-lysine-alginate (APA)-encapsulated rat Leydig cells (LCs) provides a promising approach for treating testosterone deficiency (TD). Nevertheless, LCs have a limited capacity to proliferate, limiting the efficacy of LC transplantation therapy. Here, we established an efficient differentiation system to obtain functional Leydig-like cells (LLCs) from human stem Leydig cells (hSLCs). Then we injected APA-encapsulated LLCs into the abdominal cavities of castrated mice without an immunosuppressor. The APA-encapsulated cells survived and partially restored testosterone production for 90 days in vivo. More importantly, the transplantation of encapsulated LLCs ameliorated the symptoms of TD, such as fat accumulation, muscle atrophy and adipocyte accumulation in bone marrow. Overall, these results suggest that the transplantation of encapsulated LLCs is a promising new method for testosterone supplementation with potential clinical applications in TD.


Asunto(s)
Células Inmovilizadas/trasplante , Células Intersticiales del Testículo/trasplante , Testosterona/deficiencia , Adipocitos/patología , Adolescente , Adulto , Anciano , Alginatos/química , Antígenos CD/metabolismo , Médula Ósea/patología , Cápsulas , Castración , Diferenciación Celular , Humanos , Células Intersticiales del Testículo/ultraestructura , Masculino , Persona de Mediana Edad , Atrofia Muscular/patología , Polilisina/análogos & derivados , Polilisina/química , Testosterona/metabolismo , Adulto Joven
11.
Leukemia ; 34(11): 2903-2913, 2020 11.
Artículo en Inglés | MEDLINE | ID: mdl-32733012

RESUMEN

The mutant IDH1 (mIDH1) inhibitor BAY1436032 demonstrated robust activity in preclinical AML models, supporting clinical evaluation. In the current dose-escalation study, BAY1436032 was orally administered to 27 mIDH1 AML subjects across 4 doses ranging from 300 to 1500 mg twice-daily. BAY1436032 exhibited a relatively short half-life and apparent non-linear pharmacokinetics after continuous dosing. Most subjects experienced only partial target inhibition as indicated by plasma R-2HG levels. BAY1436032 was safe and a maximum tolerated dose was not identified. The median treatment duration for all subjects was 3.0 months (0.49-8.5). The overall response rate was 15% (4/27; 1 CRp, 1 PR, 2 MLFS), with responding subjects experiencing a median treatment duration of 6.0 months (3.9-8.5) and robust R-2HG decreases. Thirty percent (8/27) achieved SD, with a median treatment duration of 5.5 months (3.1-7.0). Degree of R-2HG inhibition and clinical benefit did not correlate with dose. Although BAY1436032 was safe and modestly effective as monotherapy, the low overall response rate and incomplete target inhibition achieved at even the highest dose tested do not support further clinical development of this investigational agent in AML.


Asunto(s)
Compuestos de Anilina/uso terapéutico , Antineoplásicos/uso terapéutico , Bencimidazoles/uso terapéutico , Inhibidores Enzimáticos/uso terapéutico , Isocitrato Deshidrogenasa/antagonistas & inhibidores , Isocitrato Deshidrogenasa/genética , Leucemia Mieloide Aguda/tratamiento farmacológico , Leucemia Mieloide Aguda/genética , Terapia Molecular Dirigida , Mutación , Adulto , Anciano , Compuestos de Anilina/administración & dosificación , Compuestos de Anilina/efectos adversos , Compuestos de Anilina/farmacocinética , Antineoplásicos/administración & dosificación , Antineoplásicos/efectos adversos , Antineoplásicos/farmacocinética , Bencimidazoles/administración & dosificación , Bencimidazoles/efectos adversos , Bencimidazoles/farmacocinética , Médula Ósea/patología , Análisis Mutacional de ADN , Inhibidores Enzimáticos/administración & dosificación , Inhibidores Enzimáticos/efectos adversos , Inhibidores Enzimáticos/farmacocinética , Femenino , Humanos , Isocitrato Deshidrogenasa/metabolismo , Leucemia Mieloide Aguda/diagnóstico , Leucemia Mieloide Aguda/mortalidad , Masculino , Persona de Mediana Edad , Pronóstico , Análisis de Supervivencia , Resultado del Tratamiento
12.
Medicine (Baltimore) ; 99(34): e21876, 2020 Aug 21.
Artículo en Inglés | MEDLINE | ID: mdl-32846844

RESUMEN

BACKGROUND: Cancer continues to be a severe global health problem and the leading cause of death worldwide. Chemotherapy as the main treatment has various side effects, of which marrow suppression is the most common one. Acupuncture had shown clinical effects for marrow suppression after chemotherapy in many studies. However, the efficacy and safety of acupuncture therapy for marrow suppression after chemotherapy remains unclear. OBJECTIVE: This protocol aims to evaluate the efficacy and safety of acupuncture for marrow suppression after chemotherapy according to the existing randomized controlled trials. METHODS AND ANALYSIS: The randomized controlled trials on acupuncture therapy for marrow suppression after chemotherapy will be searched in the database of Embase, PubMed and Cochrane Library, Allied and Complementary Medicine Database (AMED), Chinese Biomedical Literature Database (CBM), China Science and Technology Journal Database (VIP), China National Knowledge Infrastructure (CNKI), WanFang Database (WF), and related registration platforms (WHO ICTRP, Clinical Trials, and Chinese Clinical Trial Register [ChiCTR]), Grey Literature Database from inception to 1 August 2020. The primary outcomes will be assessed using white blood cell (WBC) count, platelet count, hemoglobin count and the number of neutrophils (N). Review Manager V.5.3 software will be applied for statistical analyses. We will measure the risk of bias of the included studies with Cochrane Collaboration Risk of Bias Tool. Finally, Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) will be used to grade the overall quality of evidence. And we will use the intra-group correlation coefficient to assess the consistency of reviewers. RESULT: This systematic review and meta-analysis will put a high-quality synthesis of the efficacy and safety of acupuncture treatment in marrow suppression after chemotherapy. CONCLUSION: The conclusion of this systematic review will provide evidence to assess acupuncture therapy is an efficacy and safe intervention to treat and control marrow suppression after chemotherapy. PROSPERO REGISTRATION NUMBER: PROSPERO CRD42020163336.


Asunto(s)
Terapia por Acupuntura/métodos , Antineoplásicos/efectos adversos , Células de la Médula Ósea/efectos de los fármacos , Médula Ósea/efectos de los fármacos , Médula Ósea/patología , Quimioterapia/métodos , Femenino , Hemoglobinas/análisis , Humanos , Recuento de Leucocitos/métodos , Masculino , Neoplasias/tratamiento farmacológico , Neutrófilos/citología , Recuento de Plaquetas/métodos , Ensayos Clínicos Controlados Aleatorios como Asunto , Seguridad , Resultado del Tratamiento , Metaanálisis como Asunto
13.
Chem Biodivers ; 17(9): e2000295, 2020 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-32649040

RESUMEN

Collagen is widely used for dental therapy in several ways such as films, 3D matrix, and composites, besides traditional Chinese medicine (TCM), has been used in tissue regeneration and wound healing application for centuries. Hence, the present study was targeted for the first time to fabricate collagen film with TCM such as resveratrol and celastrol in order to investigate the human periodontal ligament fibroblasts (HPLF) growth and bone marrow macrophages (BMM) derived osteoclastogenesis. Further, the physicochemical, mechanical and biological activities of collagen-TCM films crosslinked by glycerol and EDC-NHS (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide-N-hydroxysulfosuccinimide) were investigated. Collagen film characterization was significantly regulated by the nature of plasticizers like hydrophobic and degree of polarity. Interestingly, the collagen film's denaturation temperature was increased by EDC-NHS than glycerol. FT-IR data confirmed the functional group changes due to chemical interaction of collagen with TCM. Morphological changes of HPLF cells cultured in control and collagen films were observed by SEM. Importantly, the addition of resveratrol upregulated the proliferation of HPLF cells, while osteoclastogenesis of BMM cells treated with mCSF-RANKL was significantly downregulated by celastrol. Accordingly, the collagen-TCM film could be an interesting material for dental regeneration, and especially it is a therapeutic target to restrain the elevated bone resorption during osteoporosis.


Asunto(s)
Antioxidantes/farmacología , Colágeno/farmacología , Implantes Dentales , Triterpenos Pentacíclicos/farmacología , Ligamento Periodontal/efectos de los fármacos , Resveratrol/farmacología , Antioxidantes/química , Compuestos de Bifenilo/antagonistas & inhibidores , Médula Ósea/efectos de los fármacos , Médula Ósea/patología , Proliferación Celular/efectos de los fármacos , Células Cultivadas , Colágeno/química , Relación Dosis-Respuesta a Droga , Fibroblastos/efectos de los fármacos , Fibroblastos/patología , Humanos , Macrófagos/efectos de los fármacos , Macrófagos/patología , Estructura Molecular , Osteogénesis/efectos de los fármacos , Triterpenos Pentacíclicos/química , Ligamento Periodontal/patología , Picratos/antagonistas & inhibidores , Resveratrol/química , Relación Estructura-Actividad
14.
Biochim Biophys Acta Rev Cancer ; 1874(1): 188387, 2020 08.
Artículo en Inglés | MEDLINE | ID: mdl-32579889

RESUMEN

Late detection, compromised immune system, and chemotherapy resistance underlie the poor patient prognosis for pancreatic ductal adenocarcinoma (PDAC) patients, making it the 3rd leading cause of cancer-related deaths in the United States. Cooperation between the tumor cells and the immune system leads to the immune escape and eventual establishment of the tumor. For more than 20 years, sincere efforts have been made to intercept the tumor-immune crosstalk and identify the probable therapeutic targets for breaking self-tolerance toward tumor antigens. However, the success of these studies depends on detailed examination and understanding of tumor-immune cell interactions, not only in the primary tumor but also at distant systemic niches. Innate and adaptive arms of the immune system sculpt tumor immunogenicity, where they not only aid in providing an amenable environment for their survival but also act as a driver for tumor relapse at primary or distant organ sites. This review article highlights the key events associated with tumor-immune communication and associated immunosuppression at both local and systemic microenvironments in PDAC. Furthermore, we discuss the approaches and benefits of targeting both local and systemic immunosuppression for PDAC patients. The present articles integrate data from clinical and genetic mouse model studies to provide a widespread consensus on the role of local and systemic immunosuppression in undermining the anti-tumor immune responses against PDAC.


Asunto(s)
Carcinoma Ductal Pancreático/terapia , Inmunoterapia/métodos , Neoplasias Pancreáticas/terapia , Escape del Tumor/efectos de los fármacos , Microambiente Tumoral/inmunología , Inmunidad Adaptativa/efectos de los fármacos , Animales , Antineoplásicos Inmunológicos/farmacología , Antineoplásicos Inmunológicos/uso terapéutico , Protocolos de Quimioterapia Combinada Antineoplásica/farmacología , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Médula Ósea/efectos de los fármacos , Médula Ósea/inmunología , Médula Ósea/patología , Vacunas contra el Cáncer/administración & dosificación , Carcinoma Ductal Pancreático/inmunología , Carcinoma Ductal Pancreático/mortalidad , Carcinoma Ductal Pancreático/patología , Quimioterapia Adyuvante/métodos , Ensayos Clínicos como Asunto , Terapia Combinada/métodos , Modelos Animales de Enfermedad , Supervivencia sin Enfermedad , Fluorouracilo/farmacología , Fluorouracilo/uso terapéutico , Humanos , Inmunidad Innata/efectos de los fármacos , Irinotecán/farmacología , Irinotecán/uso terapéutico , Leucovorina/farmacología , Leucovorina/uso terapéutico , Escisión del Ganglio Linfático , Ganglios Linfáticos/inmunología , Ganglios Linfáticos/patología , Ganglios Linfáticos/cirugía , Ratones , Ratones Transgénicos , Terapia Neoadyuvante/métodos , Oxaliplatino/farmacología , Oxaliplatino/uso terapéutico , Páncreas/inmunología , Páncreas/patología , Páncreas/cirugía , Pancreatectomía , Neoplasias Pancreáticas/inmunología , Neoplasias Pancreáticas/mortalidad , Neoplasias Pancreáticas/patología , Bazo/inmunología , Bazo/patología , Bazo/cirugía , Esplenectomía , Linfocitos T/efectos de los fármacos , Linfocitos T/inmunología , Linfocitos T/trasplante , Trasplante Autólogo/métodos
15.
J Pak Med Assoc ; 70(5): 923-925, 2020 May.
Artículo en Inglés | MEDLINE | ID: mdl-32400755

RESUMEN

Megaloblastic anaemia due to vitamin B12 and folic acid deficiency is uncommon in infancy and rarely reported in infants below 3 months of age. We hereby report a case of megaloblastic anaemia in a 9-weeks old infant having fever from 7th week of life. Blood picture showed pancytopenia and diagnosis was confirmed on bone marrow biopsy and serum level of vitamins. Patient positively responded to vitamin B12 and folic acid supplementation. Infants with pancytopenia even younger than 2 months, should also be investigated for vitamin B12 and folate deficiency. Mother of the baby was not antenatally investigated for anaemia. Prompt antenatal diagnosis and treatment of mothers can reduce the incidence in the infants.


Asunto(s)
Anemia Megaloblástica , Médula Ósea/patología , Deficiencia de Ácido Fólico , Ácido Fólico , Deficiencia de Vitamina B 12 , Vitamina B 12 , Anemia Megaloblástica/sangre , Anemia Megaloblástica/diagnóstico , Anemia Megaloblástica/etiología , Anemia Megaloblástica/terapia , Diagnóstico Diferencial , Diagnóstico Precoz , Intervención Médica Temprana/métodos , Insuficiencia de Crecimiento/diagnóstico , Insuficiencia de Crecimiento/etiología , Ácido Fólico/administración & dosificación , Ácido Fólico/sangre , Deficiencia de Ácido Fólico/complicaciones , Deficiencia de Ácido Fólico/diagnóstico , Humanos , Lactante , Masculino , Pancitopenia/diagnóstico , Pancitopenia/etiología , Atención Prenatal/normas , Resultado del Tratamiento , Vitamina B 12/administración & dosificación , Vitamina B 12/sangre , Deficiencia de Vitamina B 12/complicaciones , Deficiencia de Vitamina B 12/diagnóstico , Vitaminas/administración & dosificación
16.
Biomed Res Int ; 2020: 6301697, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32280693

RESUMEN

OBJECTIVE: To investigate the therapeutic effect of combined application of Wuweizi (Schisandrae Chinensis Fructus) and dexamethasone in rats with idiopathic pulmonary fibrosis (IPF) and the possible protective effect of Wuweizi against dexamethasone-induced glucocorticoid osteoporosis (GIOP). METHODS: There were five groups in this study, including the sham operation group, model group, Wuweizi group, dexamethasone group, and the combination group. A rat IPF model was made by the endotracheal injection of bleomycin. After modeling, rats were given drug interventions for 7 and 28 days. Rats were sacrificed for pathological morphology examination of the bone and lung and quantitative determination of biochemical markers of bone metabolism and angiogenesis-related cytokine to observe therapeutic efficacy on the 7th and 28th day. ELISA was used for the quantitative determination of tartrate-resistant acid phosphatase (TRACP), bone alkaline phosphatase (BALP), hypoxia-inducible factor (HIF-1α), platelet-derived growth factor (PDGF), pigment epithelium-derived factor (PEDF), and endostatin in serum. The concentrations of calcium (Ca) and phosphorus (P) were detected with the automatic biochemical analyzer. RESULTS: After drug interventions for 7 and 28 days, alveolitis and pulmonary fibrosis in treatment groups showed significant improvement compared with those in the model group (P < 0.05). Bone histopathological figures showed severely damaged trabecular bone and bone marrow cavity in the dexamethasone group, but it was significantly alleviated in the combination group. The concentrations of BALP and Ca in the combination group were significantly higher than those in the dexamethasone group after treatment, while the concentrations of TRACP and P were lower than those in the dexamethasone group (P < 0.05). Bone histopathological figures showed severely damaged trabecular bone and bone marrow cavity in the dexamethasone group, but it was significantly alleviated in the combination group. The concentrations of BALP and Ca in the combination group were significantly higher than those in the dexamethasone group after treatment, while the concentrations of TRACP and P were lower than those in the dexamethasone group (α), platelet-derived growth factor (PDGF), pigment epithelium-derived factor (PEDF), and endostatin in serum. The concentrations of calcium (Ca) and phosphorus (P) were detected with the automatic biochemical analyzer. P < 0.05). Bone histopathological figures showed severely damaged trabecular bone and bone marrow cavity in the dexamethasone group, but it was significantly alleviated in the combination group. The concentrations of BALP and Ca in the combination group were significantly higher than those in the dexamethasone group after treatment, while the concentrations of TRACP and P were lower than those in the dexamethasone group (P < 0.05). Bone histopathological figures showed severely damaged trabecular bone and bone marrow cavity in the dexamethasone group, but it was significantly alleviated in the combination group. The concentrations of BALP and Ca in the combination group were significantly higher than those in the dexamethasone group after treatment, while the concentrations of TRACP and P were lower than those in the dexamethasone group (α), platelet-derived growth factor (PDGF), pigment epithelium-derived factor (PEDF), and endostatin in serum. The concentrations of calcium (Ca) and phosphorus (P) were detected with the automatic biochemical analyzer. CONCLUSIONS: The combination therapy of Wuweizi and dexamethasone effectively treated IPF rats by regulating angiogenesis, meanwhile distinctly alleviating dexamethasone-induced GIOP.


Asunto(s)
Medicamentos Herbarios Chinos/farmacología , Glucocorticoides/uso terapéutico , Fibrosis Pulmonar Idiopática/complicaciones , Osteoporosis/tratamiento farmacológico , Extractos Vegetales/uso terapéutico , Schisandra/química , Animales , Factores de Transcripción con Motivo Hélice-Asa-Hélice Básico/metabolismo , Bleomicina/efectos adversos , Médula Ósea/metabolismo , Médula Ósea/patología , Huesos/patología , Hueso Esponjoso/patología , Dexametasona , Modelos Animales de Enfermedad , Endostatinas/metabolismo , Proteínas del Ojo/metabolismo , Fibrosis Pulmonar Idiopática/patología , Pulmón/metabolismo , Pulmón/patología , Masculino , Factores de Crecimiento Nervioso/metabolismo , Osteoporosis/inducido químicamente , Osteoporosis/patología , Factor de Crecimiento Derivado de Plaquetas/metabolismo , Ratas , Ratas Wistar , Serpinas/metabolismo , Fosfatasa Ácida Tartratorresistente
17.
Exp Hematol ; 84: 54-66, 2020 04.
Artículo en Inglés | MEDLINE | ID: mdl-32240658

RESUMEN

Exposure to high-dose total body irradiation (TBI) can result in hematopoietic acute radiation syndrome (H-ARS), characterized by leukopenia, anemia, and coagulopathy. Death from H-ARS occurs from hematopoietic insufficiency and opportunistic infections. Following radiation exposure, red blood cells (RBCs) undergo hemolysis from radiation-induced hemoglobin denaturation, causing the release of iron. Free iron can have multiple detrimental biological effects, including suppression of hematopoiesis. We investigated the impact of radiation-induced iron release on the bone marrow following TBI and the potential impact of the ACE inhibitor captopril, which improves survival from H-ARS. C57BL/6J mice were exposed to 7.9 Gy, 60Co irradiation, 0.6 Gy/min (LD70-90/30). RBCs and reticulocytes were significantly reduced within 7 days of TBI, with the RBC nadir at 14-21 days. Iron accumulation in the bone marrow correlated with the time course of RBC hemolysis, with an ∼10-fold increase in bone marrow iron at 14-21 days post-irradiation, primarily within the cytoplasm of macrophages. Iron accumulation in the bone marrow was associated with increased expression of genes for iron binding and transport proteins, including transferrin, transferrin receptor 1, ferroportin, and integrin αMß2. Expression of the gene encoding Nrf2, a transcription factor activated by oxidative stress, also increased at 21 days post-irradiation. Captopril did not alter iron accumulation in the bone marrow or expression of iron storage genes, but did suppress Nrf2 expression. Our study suggests that following TBI, iron is deposited in tissues not normally associated with iron storage, which may be a secondary mechanism of radiation-induced tissue injury.


Asunto(s)
Síndrome de Radiación Aguda/metabolismo , Médula Ósea/metabolismo , Rayos gamma/efectos adversos , Hematopoyesis/efectos de la radiación , Hierro/metabolismo , Traumatismos Experimentales por Radiación/metabolismo , Síndrome de Radiación Aguda/genética , Síndrome de Radiación Aguda/patología , Animales , Médula Ósea/patología , Captopril/farmacología , Eritrocitos/metabolismo , Eritrocitos/patología , Femenino , Regulación de la Expresión Génica/efectos de los fármacos , Regulación de la Expresión Génica/efectos de la radiación , Hematopoyesis/efectos de los fármacos , Hematopoyesis/genética , Ratones , Ratones Transgénicos , Factor 2 Relacionado con NF-E2/biosíntesis , Factor 2 Relacionado con NF-E2/genética , Traumatismos Experimentales por Radiación/genética , Traumatismos Experimentales por Radiación/patología
18.
Asian Pac J Cancer Prev ; 21(3): 771-775, 2020 Mar 01.
Artículo en Inglés | MEDLINE | ID: mdl-32212806

RESUMEN

INTRODUCTION: Bone marrow biopsy is a common procedure for the diagnosis and treatment of hematologic diseases and tumors, which are associated with anxiety. The purpose of this study was to examine the effect of lavender aroma on anxiety of patients having bone marrow biopsy. MATERIALS AND METHODS: This study was performed on 80 patients referred to Vali-e-Asr Hospital for bone marrow biopsy. Samples were selected by convenience method and were assigned into intervention and control groups using randomized blocks of 4. Random sequence was generated by RAS software. Several drops of distilled water on a cotton ball was used in the control group and same amount of lavender essential oil on a cotton ball was used in the intervention group. Then, participants in both groups were asked to smell the cotton ball for 15 minutes and then, their anxiety level was measured immediately. The results were analyzed by SPSS software version 25 using covariance analysis and rank regression. RESULTS: The results showed that, the mean scores of anxiety in the control and intervention groups were 6.3 ± 1.92 and 3.75 ± 1.05, respectively. There was a significant difference (p <0.05) between the two groups in terms of anxiety score.The results showed that there was a significant difference in anxiety score between two groups in terms of variables such as age, gender, physician experience, biopsy history and biopsy site (P <0.05). The results also showed no significant difference between the (p >0.05). CONCLUSION: The results of this study showed that bone marrow biopsy is associated with anxiety, and smelling of lavender aroma is effective in reducing anxiety in patients undergoing this procedure. This fragrance can be used by treatment team in hematology and oncology clinics to reduce anxiety caused by bone marrow biopsy.
.


Asunto(s)
Ansiedad/prevención & control , Biopsia , Médula Ósea , Lavandula/química , Aceites Volátiles/uso terapéutico , Aceites de Plantas/uso terapéutico , Adulto , Ansiedad/etiología , Aromaterapia , Biopsia/efectos adversos , Médula Ósea/patología , Femenino , Humanos , Masculino , Persona de Mediana Edad , Odorantes
19.
Br J Haematol ; 189(5): 815-825, 2020 06.
Artículo en Inglés | MEDLINE | ID: mdl-32135579

RESUMEN

Acute myeloid leukaemia (AML) is the most common adult acute leukaemia with the lowest survival rate. It is characterised by a build-up of immature myeloid cells anchored in the protective niche of the bone marrow (BM) microenvironment. The CXCL12/CXCR4 axis is central to the pathogenesis of AML as it has fundamental control over AML cell adhesion into the protective BM niche, adaptation to the hypoxic environment, cellular migration and survival. High levels of CXCR4 expression are associated with poor relapse-free and overall survival. The CXCR4 ligand, CXCL12 (SDF-1), is expressed by multiple cells types in the BM, facilitating the adhesion and survival of the malignant clone. Blocking the CXCL12/CXCR4 axis is an attractive therapeutic strategy providing a 'multi-hit' therapy that both prevents essential survival signals and releases the AML cells from the BM into the circulation. Once out of the protective niche of the BM they would be more susceptible to destruction by conventional chemotherapeutic drugs. In this review, we disentangle the diverse roles of the CXCL12/CXCR4 axis in AML. We then describe multiple CXCR4 inhibitors, including small molecules, peptides, or monoclonal antibodies, which have been developed to date and their progress in pre-clinical and clinical trials. Finally, the review leads us to the conclusion that there is a need for further investigation into the development of a 'multi-hit' therapy that targets several signalling pathways related to AML cell adhesion and maintenance in the BM.


Asunto(s)
Quimiocina CXCL12/fisiología , Leucemia Mieloide Aguda/metabolismo , Proteínas de Neoplasias/fisiología , Receptores CXCR4/fisiología , Transducción de Señal/fisiología , Animales , Anticuerpos Monoclonales Humanizados/uso terapéutico , Antineoplásicos/sangre , Antineoplásicos/farmacología , Antineoplásicos/uso terapéutico , Bencilaminas , Médula Ósea/patología , Adhesión Celular/efectos de los fármacos , Adhesión Celular/fisiología , Hipoxia de la Célula , Movimiento Celular/fisiología , Micropartículas Derivadas de Células , Ensayos Clínicos como Asunto , Ciclamas , Evaluación Preclínica de Medicamentos , Resistencia a Antineoplásicos , Regulación Leucémica de la Expresión Génica/efectos de los fármacos , Regulación Leucémica de la Expresión Génica/fisiología , Compuestos Heterocíclicos/farmacología , Compuestos Heterocíclicos/uso terapéutico , Humanos , Leucemia Mieloide Aguda/sangre , Leucemia Mieloide Aguda/tratamiento farmacológico , Leucemia Mieloide Aguda/patología , Ratones , Terapia Molecular Dirigida , Proteínas de Neoplasias/antagonistas & inhibidores , Células Madre Neoplásicas/metabolismo , Células Madre Neoplásicas/patología , Péptidos/uso terapéutico , Péptidos Cíclicos/uso terapéutico , Piridinas/uso terapéutico , Receptores CXCR4/antagonistas & inhibidores , Transducción de Señal/efectos de los fármacos , Nicho de Células Madre , Células del Estroma/metabolismo , Células del Estroma/patología , Microambiente Tumoral
20.
Curr Osteoporos Rep ; 18(1): 47-56, 2020 02.
Artículo en Inglés | MEDLINE | ID: mdl-32060718

RESUMEN

PURPOSE OF REVIEW: The goal of this review is to highlight the deficits in muscle and bone in children with cerebral palsy (CP), discuss the muscle-bone relationship in the CP population, and identify muscle-based intervention strategies that may stimulate an improvement in their bone development. RECENT FINDINGS: The latest research suggests that muscle and bone are both severely underdeveloped and weak in children with CP, even in ambulatory children with mild forms of the disorder. The small and low-performing muscles and limited participation in physical activity are likely the major contributors to the poor bone development in children with CP. However, the muscle-bone relationship may be complicated by other factors, such as a high degree of fat and collagen infiltration of muscle, atypical muscle activation, and muscle spasticity. Muscle-based interventions, such as resistance training, vibration, and nutritional supplementation, have the potential to improve bone development in children with CP, especially if they are initiated before puberty. Studies are needed to identify the muscle-related factors with the greatest influence on bone development in children with CP. Identifying treatment strategies that capitalize on the relationship between muscle and bone, while also improving balance, coordination, and physical activity participation, is an important step toward increasing bone strength and minimizing fractures in children with CP.


Asunto(s)
Desarrollo Óseo/fisiología , Huesos/fisiopatología , Parálisis Cerebral/fisiopatología , Espasticidad Muscular/fisiopatología , Músculo Esquelético/fisiopatología , Osteoporosis/fisiopatología , Fracturas Osteoporóticas , Tejido Adiposo , Densidad Ósea , Médula Ósea/patología , Parálisis Cerebral/rehabilitación , Niño , Colágeno , Ejercicio Físico , Humanos , Fuerza Muscular , Músculo Esquelético/patología , Tamaño de los Órganos , Entrenamiento de Fuerza , Vibración/uso terapéutico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA